239 related articles for article (PubMed ID: 20016205)
21. c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions.
Hibbert B; Chen YX; O'Brien ER
Am J Physiol Heart Circ Physiol; 2004 Aug; 287(2):H518-24. PubMed ID: 15277195
[TBL] [Abstract][Full Text] [Related]
22. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries.
Nakano K; Egashira K; Masuda S; Funakoshi K; Zhao G; Kimura S; Matoba T; Sueishi K; Endo Y; Kawashima Y; Hara K; Tsujimoto H; Tominaga R; Sunagawa K
JACC Cardiovasc Interv; 2009 Apr; 2(4):277-83. PubMed ID: 19463437
[TBL] [Abstract][Full Text] [Related]
23. Wnt16 attenuates TGFβ-induced chondrogenic transformation in vascular smooth muscle.
Beazley KE; Nurminsky D; Lima F; Gandhi C; Nurminskaya MV
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):573-9. PubMed ID: 25614285
[TBL] [Abstract][Full Text] [Related]
24. Drug-eluting stent specifically designed to target vascular smooth muscle cell phenotypic modulation attenuated restenosis through the YAP pathway.
Huang C; Zhang W; Zhu Y
Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H541-H551. PubMed ID: 31298560
[TBL] [Abstract][Full Text] [Related]
25. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions.
Zhou Y; Poczatek MH; Berecek KH; Murphy-Ullrich JE
Biochem Biophys Res Commun; 2006 Jan; 339(2):633-41. PubMed ID: 16310163
[TBL] [Abstract][Full Text] [Related]
26. Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells.
Dey NB; Boerth NJ; Murphy-Ullrich JE; Chang PL; Prince CW; Lincoln TM
Circ Res; 1998 Feb; 82(2):139-46. PubMed ID: 9468184
[TBL] [Abstract][Full Text] [Related]
27. Ligand-Activated Peroxisome Proliferator-Activated Receptor δ Attenuates Vascular Oxidative Stress by Inhibiting Thrombospondin-1 Expression.
Ahn MY; Ham SA; Yoo T; Lee WJ; Hwang JS; Paek KS; Lim DS; Han SG; Lee CH; Seo HG
J Vasc Res; 2018; 55(2):75-86. PubMed ID: 29408825
[TBL] [Abstract][Full Text] [Related]
28. In Vitro Lineage-Specific Differentiation of Vascular Smooth Muscle Cells in Response to SMAD3 Deficiency: Implications for SMAD3-Related Thoracic Aortic Aneurysm.
Gong J; Zhou D; Jiang L; Qiu P; Milewicz DM; Chen YE; Yang B
Arterioscler Thromb Vasc Biol; 2020 Jul; 40(7):1651-1663. PubMed ID: 32404006
[TBL] [Abstract][Full Text] [Related]
29. ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells.
Li P; Oparil S; Novak L; Cao X; Shi W; Lucas J; Chen YF
J Appl Physiol (1985); 2007 Jan; 102(1):390-8. PubMed ID: 17038494
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis.
Sinnaeve P; Chiche JD; Gillijns H; Van Pelt N; Wirthlin D; Van De Werf F; Collen D; Bloch KD; Janssens S
Circulation; 2002 Jun; 105(24):2911-6. PubMed ID: 12070122
[TBL] [Abstract][Full Text] [Related]
31. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
Rosner D; McCarthy N; Bennett M
Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
[TBL] [Abstract][Full Text] [Related]
33. The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis.
Luo H; Zhou C; Chi J; Pan S; Lin H; Gao F; Ni T; Meng L; Zhang J; Jiang C; Ji Z; Lv H; Guo H
Cardiovasc Drugs Ther; 2019 Feb; 33(1):25-33. PubMed ID: 30663009
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.
Torella D; Curcio A; Gasparri C; Galuppo V; De Serio D; Surace FC; Cavaliere AL; Leone A; Coppola C; Ellison GM; Indolfi C
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2935-43. PubMed ID: 17293493
[TBL] [Abstract][Full Text] [Related]
35. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
[TBL] [Abstract][Full Text] [Related]
36. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells.
McGillicuddy FC; O'Toole D; Hickey JA; Gallagher WM; Dawson KA; Keenan AK
Vascul Pharmacol; 2006 Jun; 44(6):469-75. PubMed ID: 16624629
[TBL] [Abstract][Full Text] [Related]
37. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo.
Daniel C; Wiede J; Krutzsch HC; Ribeiro SM; Roberts DD; Murphy-Ullrich JE; Hugo C
Kidney Int; 2004 Feb; 65(2):459-68. PubMed ID: 14717916
[TBL] [Abstract][Full Text] [Related]
38. Transforming growth factor-beta: a promising target for anti-stenosis therapy.
Chamberlain J
Cardiovasc Drug Rev; 2001; 19(4):329-44. PubMed ID: 11830751
[TBL] [Abstract][Full Text] [Related]
39. Enhanced sterol response element-binding protein in postintervention restenotic blood vessels plays an important role in vascular smooth muscle proliferation.
Zhou RH; Pesant S; Cohn HI; Eckhart AD
Life Sci; 2008 Jan; 82(3-4):174-81. PubMed ID: 18068195
[TBL] [Abstract][Full Text] [Related]
40. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
